Fig. 1From: The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsPFS and OS according to cfDNA best cut-off value in the overall population (A and B), and PFS in immunotherapy (C) and in VEGFR-TKI (D) treated patientsBack to article page